Bogomolova N S, Bronskaia L K, Sorokina V I, Bol'shakov L V, Vinogradova L N
Antibiot Khimioter. 1992 Aug;37(8):6-9.
The results of the clinical trials of cefoperazone (cefobid, Pfizer, USA), a 3rd generation cephalosporin, carried out at the Research Centre of Surgery are presented. The antibiotic was used to treat and prevent postoperative infections in 44 patients. Good and satisfactory results were observed in 43 out of the 44 patients (99.9 per cent). Antimicrobial activity of cefoperazone against 182 bacterial strains isolated from the patients was assayed and compared with that of other cephalosporins i.e. cefotaxime, ceftriaxone and ceftazidime. The cefoperazone pharmacokinetics was studied in the patients with normal renal functions after surgical operations on the organs of the chest and abdominal cavity. The antibiotic was shown useful in the monotherapy of mixed infections involving anaerobic pathogens.
本文展示了在外科研究中心进行的第三代头孢菌素头孢哌酮（头孢必妥，美国辉瑞公司）的临床试验结果。该抗生素用于治疗和预防44例患者的术后感染。44例患者中有43例（99.9%）观察到良好和满意的结果。对从患者中分离出的182株细菌菌株测定了头孢哌酮的抗菌活性，并与其他头孢菌素即头孢噻肟、头孢曲松和头孢他啶的抗菌活性进行了比较。在胸部和腹腔器官手术后肾功能正常的患者中研究了头孢哌酮的药代动力学。结果表明，该抗生素在涉及厌氧菌病原体的混合感染的单药治疗中有效。
